202 related articles for article (PubMed ID: 21856360)
21. HPV vaccination: vaccine acceptance, side effects and screening intentions.
Paul-Ebhohimhen V; Huc S; Tissington H; Oates K; Stark C
Community Pract; 2010 Jun; 83(6):30-3. PubMed ID: 20586376
[TBL] [Abstract][Full Text] [Related]
22. Quantifying the impact of dissimilar HPV vaccination uptake among Manitoban school girls by ethnicity using a transmission dynamic model.
Shafer LA; Jeffrey I; Elias B; Shearer B; Canfell K; Kliewer E
Vaccine; 2013 Oct; 31(42):4848-55. PubMed ID: 23933332
[TBL] [Abstract][Full Text] [Related]
23. Human papillomavirus vaccine initiation among adolescent girls in high-risk communities.
Guerry SL; De Rosa CJ; Markowitz LE; Walker S; Liddon N; Kerndt PR; Gottlieb SL
Vaccine; 2011 Mar; 29(12):2235-41. PubMed ID: 21288799
[TBL] [Abstract][Full Text] [Related]
24. Modeling the impact of screening policy and screening compliance on incidence and mortality of cervical cancer in the post-HPV vaccination era.
de Blasio BF; Neilson AR; Klemp M; Skjeldestad FE
J Public Health (Oxf); 2012 Dec; 34(4):539-47. PubMed ID: 22707556
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening.
Thiry N; De Laet C; Hulstaert F; Neyt M; Huybrechts M; Cleemput I
Int J Technol Assess Health Care; 2009 Apr; 25(2):161-70. PubMed ID: 19366497
[TBL] [Abstract][Full Text] [Related]
27. Is there an association between maternal pap test use and adolescent human papillomavirus vaccination?
Monnat SM; Wallington SF
J Adolesc Health; 2013 Feb; 52(2):212-8. PubMed ID: 23332487
[TBL] [Abstract][Full Text] [Related]
28. Socioeconomic predictors of human papillomavirus vaccination among girls in the Danish childhood immunization program.
Slåttelid Schreiber SM; Juul KE; Dehlendorff C; Kjær SK
J Adolesc Health; 2015 Apr; 56(4):402-7. PubMed ID: 25659994
[TBL] [Abstract][Full Text] [Related]
29. Preventing cervical cancer through human papillomavirus vaccination: perspective from focus groups.
Wong LP
J Low Genit Tract Dis; 2009 Apr; 13(2):85-93. PubMed ID: 19387128
[TBL] [Abstract][Full Text] [Related]
30. HPV vaccine acceptability in Ghana, West Africa.
Coleman MA; Levison J; Sangi-Haghpeykar H
Vaccine; 2011 May; 29(23):3945-50. PubMed ID: 21481327
[TBL] [Abstract][Full Text] [Related]
31. HPV vaccine uptake among daughters of Latinx immigrant mothers: Findings from a cluster randomized controlled trial of a community-based, culturally relevant intervention.
Scarinci IC; Hansen B; Kim YI
Vaccine; 2020 May; 38(25):4125-4134. PubMed ID: 32354671
[TBL] [Abstract][Full Text] [Related]
32. Uptake of HPV vaccine: demographics, sexual history and values, parenting style, and vaccine attitudes.
Rosenthal SL; Rupp R; Zimet GD; Meza HM; Loza ML; Short MB; Succop PA
J Adolesc Health; 2008 Sep; 43(3):239-45. PubMed ID: 18710678
[TBL] [Abstract][Full Text] [Related]
33. Dynamics of HPV vaccination initiation in Flanders (Belgium) 2007-2009: a Cox regression model.
Lefevere E; Hens N; De Smet F; Van Damme P
BMC Public Health; 2011 Jun; 11():470. PubMed ID: 21672202
[TBL] [Abstract][Full Text] [Related]
34. Acceptability and uptake of female adolescent HPV vaccination in Hong Kong: a survey of mothers and adolescents.
Choi HC; Leung GM; Woo PP; Jit M; Wu JT
Vaccine; 2013 Dec; 32(1):78-84. PubMed ID: 24188759
[TBL] [Abstract][Full Text] [Related]
35. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
Adams M; Jasani B; Fiander A
Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
[TBL] [Abstract][Full Text] [Related]
36. Mothers' preferences and willingness to pay for vaccinating daughters against human papillomavirus.
Brown DS; Johnson FR; Poulos C; Messonnier ML
Vaccine; 2010 Feb; 28(7):1702-8. PubMed ID: 20044060
[TBL] [Abstract][Full Text] [Related]
37. Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain.
Gauthier A; Martín-Escudero V; Moore L; Ferko N; de Sanjosé S; Pérez-Escolano I; Catalá-López F; Ferrer E; Bosch FX
Eur J Public Health; 2008 Dec; 18(6):674-80. PubMed ID: 18641420
[TBL] [Abstract][Full Text] [Related]
38. Maternal Factors and Sexual Orientation-Related Disparities in Cervical Cancer Prevention.
Charlton BM; Kahn JA; Sarda V; Katz-Wise SL; Spiegelman D; Missmer SA; Austin SB
Womens Health Issues; 2019; 29(3):238-244. PubMed ID: 30639277
[TBL] [Abstract][Full Text] [Related]
39. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era.
Tota J; Mahmud SM; Ferenczy A; Coutlée F; Franco EL
Sex Health; 2010 Sep; 7(3):376-82. PubMed ID: 20719230
[TBL] [Abstract][Full Text] [Related]
40. Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan.
Tay SK; Ngan HY; Chu TY; Cheung AN; Tay EH
Vaccine; 2008 Aug; 26 Suppl 12():M60-70. PubMed ID: 18945415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
